For Sun Pharma, its investment in speciality business is paying off, as it is becoming a driver of growth for the company’s US business. Cipla’s ‘One India’ strategy, focusing on branded prescription, trade generics and consumer health brands, is leading to continued core portfolio momentum across businesses.
Tech View: Nifty charts throw up dark clouds. What traders should do next week
Nifty’s short-term trend seems to have reversed down after a reasonable rise from the lows. Immediate support is placed at 22,300 and the weakness below
April 26, 2024